- Galena Biopharma (GALE -6.8%) Q3 results ($M): Revenues: 1.6 (+38.5%); Costs and Expenses: 14.8 (+83.9%); Operating Loss: (13.2) (-91.6%); Net Loss: (6.2) (+33.5%); Loss Per Share: (0.05) (+54.5%); Quick Assets: 24.6 (-48.4%).
- NeuVax Phase 3 Present trial status: 533 of 700 patients treated.
- 2014 Guidance: Abstral revenue: $8M - 10M.
Galena Q3 revenues up 38%
Recommended For You
More Trending News
About SLS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SLS | - | - |
SELLAS Life Sciences Group, Inc. |